ArticleInflammopharmacology2026
Dual anti-inflammatory and immunomodulatory effects of clove essential oil and eugenol: targeting neutrophil functions and experimental arthritis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clove oil in combination with flurbiprofen attenuated imiquimod-induced psoriasis-like skin inflammation in a mouse model: A mechanistic study.Inflammopharmacology · 2026Article
- Article
- Concurrent phenylketonuria and immune-mediated central nervous system involvement: a case report highlighting rare co-occurrence.BMC neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymorphonuclear neutrophils (PMNs) contribute to the pathogenesis of arthritis by releasing excessive reactive oxygen species (ROS) and proteolytic enzymes, leading to joint damage. Targeting PMNs activation represents a promising therapeutic approach. This study aimed to evaluate the immunomodulatory and anti-arthritic effects of clove essential oil (CEO) and its main constituent, eugenol, through in vitro, in vivo, and in silico approaches. CEO chemical composition was determined by GC-MS. In vitro assays assessed PMNs degranulation (lysozyme release) and oxidative burst (NBT reduction), along with antioxidant, anti-hemolytic, and antiplatelet activities. Arthritis was induced in mice by CFA injection, and therapeutic efficacy was evaluated by paw edema, histopathology, and body weight monitoring. Molecular docking was conducted to predict interactions with inflammatory targets (COX-1, COX-2, TNF-α). GC-MS revealed 77.67% eugenol in CEO. Both CEO and eugenol significantly inhibited PMN degranulation (52.81% and 57.54%) and oxidative burst (41.85% and 75.41%; p < 0.001). CEO and eugenol also displayed strong antioxidant and anti-hemolytic activities, and reduced collagen-induced platelet aggregation. In vivo, treatment markedly reduced paw edema and histopathological damage without hepatic toxicity. Docking analysis suggested potential inhibitory interactions with COX-2 and TNF-α. CEO and eugenol exert potent anti-inflammatory and immunomodulatory effects by modulating PMNs activity, preventing oxidative stress, and alleviating arthritis symptoms. These findings highlight their therapeutic potential as natural candidates for managing arthritis and related inflammatory conditions.
Indexed as
Identifiers
41348260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.